Stage T1c prostate cancer

A heterogeneous category with widely varying prognosis

Arthur Hung, Larry Levy, Deborah A. Kuban

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

PURPOSE: Stage T1c prostate cancer is defined as nonpalpable disease diagnosed by needle biopsy. As more patients are being diagnosed early because of prostate-specific antigen (PSA) screening, the distribution of patients by stage has shifted dramatically. Although this group has traditionally been characterized as having early-stage disease and the best prognosis, on review of these patients, we instead found a very heterogeneous group with a wide spectrum of outcomes that depend on both patient (Gleason grade and pretreatment PSA) and treatment (dose) factors. METHODS AND MATERIALS: A retrospective analysis was performed on 353 patients with stage T1c prostate adenocarcinoma who were referred for radiation therapy from 1989-1999. All patients underwent central review of pathology. Patients were treated with external-beam radiation to doses of 60-78 Gy; 66% of the patients were treated with a dose of 70 Gy or higher. Clinical local recurrence, nodal recurrence, distant metastases, and PSA relapse were recorded. Kaplan-Meier methodology was used to determine survival. For evaluation of prognostic variables, the patients were grouped by Gleason score (2-6, 7, 8-10), pretreatment PSA level (<10, 10-20, > 20 ng/mL), and dose delivered to the prostate (≤ 70 Gy, > 70 Gy). The log-rank test was used for univariate analysis, and Cox-regression was used for multivariate analysis. RESULTS: The median age was 69 years, and the median follow-up of surviving patients was 47 months. As a percentage of all patients with prostate cancer, stage T1c continually increased from 6% in 1989 to 47% in 1999. Of the 353 patients with T1c, 66% of the patients were in the Gleason group of 2-6, 27% had a Gleason score of 7, and 7% had a Gleason score of 8-10. Sixty-five percent of the group had a pretreatment PSA level of <10 ng/ mL, 31% had a PSA level of 10-20 ng/mL, and 5% had a PSA level of > 20 ng/mL. For the entire group, the 8-year overall survival was 86%, and PSA relapse-free survival was 78%. By univariate analysis, Gleason score and pretreatment PSA were significant predictors of overall survival and PSA relapse-free survival. For PSA relapse-free survival, a radiation dose of more than 70 Gy was also a significant factor. By multivariate analysis, Gleason score, pretreatment PSA level, and radiation dose over 70 Gy were significant predictors of PSA relapse-free survival. As expected, patients with Gleason score ≤ 6 and pretreatment PSA <10 had an 8-year RFS of 90%, whereas patients with Gleason score of 8-9 and pretreatment PSA > 20 had a relapse-free survival of zero percent. DISCUSSION: Contrary to general assumption, stage T1c prostate cancer is composed of a very heterogeneous group of patients with varying outcomes. When treatment modalities and institutional data are evaluated, the spectrum of disease must be accounted for by additional prognostic factors and subset analysis. Improvement in prostate imaging and multiple core biopsies may be helpful in better defining the extent of disease in the individual patient.

Original languageEnglish (US)
Pages (from-to)440-444
Number of pages5
JournalCancer Journal
Volume8
Issue number6
DOIs
StatePublished - Nov 1 2002
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Prostate-Specific Antigen
Neoplasm Grading
Recurrence
Survival
Prostate
Radiation
Multivariate Analysis
Needle Biopsy
Statistical Factor Analysis
Adenocarcinoma
Radiotherapy
Regression Analysis
Pathology
Neoplasm Metastasis

Keywords

  • Prostate cancer
  • Radiation dose
  • Radiation therapy
  • Stage T1c

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Stage T1c prostate cancer : A heterogeneous category with widely varying prognosis. / Hung, Arthur; Levy, Larry; Kuban, Deborah A.

In: Cancer Journal, Vol. 8, No. 6, 01.11.2002, p. 440-444.

Research output: Contribution to journalArticle

Hung, Arthur ; Levy, Larry ; Kuban, Deborah A. / Stage T1c prostate cancer : A heterogeneous category with widely varying prognosis. In: Cancer Journal. 2002 ; Vol. 8, No. 6. pp. 440-444.
@article{c24b0b31e5f04c8db85c7ec325ba695e,
title = "Stage T1c prostate cancer: A heterogeneous category with widely varying prognosis",
abstract = "PURPOSE: Stage T1c prostate cancer is defined as nonpalpable disease diagnosed by needle biopsy. As more patients are being diagnosed early because of prostate-specific antigen (PSA) screening, the distribution of patients by stage has shifted dramatically. Although this group has traditionally been characterized as having early-stage disease and the best prognosis, on review of these patients, we instead found a very heterogeneous group with a wide spectrum of outcomes that depend on both patient (Gleason grade and pretreatment PSA) and treatment (dose) factors. METHODS AND MATERIALS: A retrospective analysis was performed on 353 patients with stage T1c prostate adenocarcinoma who were referred for radiation therapy from 1989-1999. All patients underwent central review of pathology. Patients were treated with external-beam radiation to doses of 60-78 Gy; 66{\%} of the patients were treated with a dose of 70 Gy or higher. Clinical local recurrence, nodal recurrence, distant metastases, and PSA relapse were recorded. Kaplan-Meier methodology was used to determine survival. For evaluation of prognostic variables, the patients were grouped by Gleason score (2-6, 7, 8-10), pretreatment PSA level (<10, 10-20, > 20 ng/mL), and dose delivered to the prostate (≤ 70 Gy, > 70 Gy). The log-rank test was used for univariate analysis, and Cox-regression was used for multivariate analysis. RESULTS: The median age was 69 years, and the median follow-up of surviving patients was 47 months. As a percentage of all patients with prostate cancer, stage T1c continually increased from 6{\%} in 1989 to 47{\%} in 1999. Of the 353 patients with T1c, 66{\%} of the patients were in the Gleason group of 2-6, 27{\%} had a Gleason score of 7, and 7{\%} had a Gleason score of 8-10. Sixty-five percent of the group had a pretreatment PSA level of <10 ng/ mL, 31{\%} had a PSA level of 10-20 ng/mL, and 5{\%} had a PSA level of > 20 ng/mL. For the entire group, the 8-year overall survival was 86{\%}, and PSA relapse-free survival was 78{\%}. By univariate analysis, Gleason score and pretreatment PSA were significant predictors of overall survival and PSA relapse-free survival. For PSA relapse-free survival, a radiation dose of more than 70 Gy was also a significant factor. By multivariate analysis, Gleason score, pretreatment PSA level, and radiation dose over 70 Gy were significant predictors of PSA relapse-free survival. As expected, patients with Gleason score ≤ 6 and pretreatment PSA <10 had an 8-year RFS of 90{\%}, whereas patients with Gleason score of 8-9 and pretreatment PSA > 20 had a relapse-free survival of zero percent. DISCUSSION: Contrary to general assumption, stage T1c prostate cancer is composed of a very heterogeneous group of patients with varying outcomes. When treatment modalities and institutional data are evaluated, the spectrum of disease must be accounted for by additional prognostic factors and subset analysis. Improvement in prostate imaging and multiple core biopsies may be helpful in better defining the extent of disease in the individual patient.",
keywords = "Prostate cancer, Radiation dose, Radiation therapy, Stage T1c",
author = "Arthur Hung and Larry Levy and Kuban, {Deborah A.}",
year = "2002",
month = "11",
day = "1",
doi = "10.1097/00130404-200211000-00007",
language = "English (US)",
volume = "8",
pages = "440--444",
journal = "Cancer journal (Sudbury, Mass.)",
issn = "1528-9117",
publisher = "Lippincott Williams and Wilkins Ltd.",
number = "6",

}

TY - JOUR

T1 - Stage T1c prostate cancer

T2 - A heterogeneous category with widely varying prognosis

AU - Hung, Arthur

AU - Levy, Larry

AU - Kuban, Deborah A.

PY - 2002/11/1

Y1 - 2002/11/1

N2 - PURPOSE: Stage T1c prostate cancer is defined as nonpalpable disease diagnosed by needle biopsy. As more patients are being diagnosed early because of prostate-specific antigen (PSA) screening, the distribution of patients by stage has shifted dramatically. Although this group has traditionally been characterized as having early-stage disease and the best prognosis, on review of these patients, we instead found a very heterogeneous group with a wide spectrum of outcomes that depend on both patient (Gleason grade and pretreatment PSA) and treatment (dose) factors. METHODS AND MATERIALS: A retrospective analysis was performed on 353 patients with stage T1c prostate adenocarcinoma who were referred for radiation therapy from 1989-1999. All patients underwent central review of pathology. Patients were treated with external-beam radiation to doses of 60-78 Gy; 66% of the patients were treated with a dose of 70 Gy or higher. Clinical local recurrence, nodal recurrence, distant metastases, and PSA relapse were recorded. Kaplan-Meier methodology was used to determine survival. For evaluation of prognostic variables, the patients were grouped by Gleason score (2-6, 7, 8-10), pretreatment PSA level (<10, 10-20, > 20 ng/mL), and dose delivered to the prostate (≤ 70 Gy, > 70 Gy). The log-rank test was used for univariate analysis, and Cox-regression was used for multivariate analysis. RESULTS: The median age was 69 years, and the median follow-up of surviving patients was 47 months. As a percentage of all patients with prostate cancer, stage T1c continually increased from 6% in 1989 to 47% in 1999. Of the 353 patients with T1c, 66% of the patients were in the Gleason group of 2-6, 27% had a Gleason score of 7, and 7% had a Gleason score of 8-10. Sixty-five percent of the group had a pretreatment PSA level of <10 ng/ mL, 31% had a PSA level of 10-20 ng/mL, and 5% had a PSA level of > 20 ng/mL. For the entire group, the 8-year overall survival was 86%, and PSA relapse-free survival was 78%. By univariate analysis, Gleason score and pretreatment PSA were significant predictors of overall survival and PSA relapse-free survival. For PSA relapse-free survival, a radiation dose of more than 70 Gy was also a significant factor. By multivariate analysis, Gleason score, pretreatment PSA level, and radiation dose over 70 Gy were significant predictors of PSA relapse-free survival. As expected, patients with Gleason score ≤ 6 and pretreatment PSA <10 had an 8-year RFS of 90%, whereas patients with Gleason score of 8-9 and pretreatment PSA > 20 had a relapse-free survival of zero percent. DISCUSSION: Contrary to general assumption, stage T1c prostate cancer is composed of a very heterogeneous group of patients with varying outcomes. When treatment modalities and institutional data are evaluated, the spectrum of disease must be accounted for by additional prognostic factors and subset analysis. Improvement in prostate imaging and multiple core biopsies may be helpful in better defining the extent of disease in the individual patient.

AB - PURPOSE: Stage T1c prostate cancer is defined as nonpalpable disease diagnosed by needle biopsy. As more patients are being diagnosed early because of prostate-specific antigen (PSA) screening, the distribution of patients by stage has shifted dramatically. Although this group has traditionally been characterized as having early-stage disease and the best prognosis, on review of these patients, we instead found a very heterogeneous group with a wide spectrum of outcomes that depend on both patient (Gleason grade and pretreatment PSA) and treatment (dose) factors. METHODS AND MATERIALS: A retrospective analysis was performed on 353 patients with stage T1c prostate adenocarcinoma who were referred for radiation therapy from 1989-1999. All patients underwent central review of pathology. Patients were treated with external-beam radiation to doses of 60-78 Gy; 66% of the patients were treated with a dose of 70 Gy or higher. Clinical local recurrence, nodal recurrence, distant metastases, and PSA relapse were recorded. Kaplan-Meier methodology was used to determine survival. For evaluation of prognostic variables, the patients were grouped by Gleason score (2-6, 7, 8-10), pretreatment PSA level (<10, 10-20, > 20 ng/mL), and dose delivered to the prostate (≤ 70 Gy, > 70 Gy). The log-rank test was used for univariate analysis, and Cox-regression was used for multivariate analysis. RESULTS: The median age was 69 years, and the median follow-up of surviving patients was 47 months. As a percentage of all patients with prostate cancer, stage T1c continually increased from 6% in 1989 to 47% in 1999. Of the 353 patients with T1c, 66% of the patients were in the Gleason group of 2-6, 27% had a Gleason score of 7, and 7% had a Gleason score of 8-10. Sixty-five percent of the group had a pretreatment PSA level of <10 ng/ mL, 31% had a PSA level of 10-20 ng/mL, and 5% had a PSA level of > 20 ng/mL. For the entire group, the 8-year overall survival was 86%, and PSA relapse-free survival was 78%. By univariate analysis, Gleason score and pretreatment PSA were significant predictors of overall survival and PSA relapse-free survival. For PSA relapse-free survival, a radiation dose of more than 70 Gy was also a significant factor. By multivariate analysis, Gleason score, pretreatment PSA level, and radiation dose over 70 Gy were significant predictors of PSA relapse-free survival. As expected, patients with Gleason score ≤ 6 and pretreatment PSA <10 had an 8-year RFS of 90%, whereas patients with Gleason score of 8-9 and pretreatment PSA > 20 had a relapse-free survival of zero percent. DISCUSSION: Contrary to general assumption, stage T1c prostate cancer is composed of a very heterogeneous group of patients with varying outcomes. When treatment modalities and institutional data are evaluated, the spectrum of disease must be accounted for by additional prognostic factors and subset analysis. Improvement in prostate imaging and multiple core biopsies may be helpful in better defining the extent of disease in the individual patient.

KW - Prostate cancer

KW - Radiation dose

KW - Radiation therapy

KW - Stage T1c

UR - http://www.scopus.com/inward/record.url?scp=0036835976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036835976&partnerID=8YFLogxK

U2 - 10.1097/00130404-200211000-00007

DO - 10.1097/00130404-200211000-00007

M3 - Article

VL - 8

SP - 440

EP - 444

JO - Cancer journal (Sudbury, Mass.)

JF - Cancer journal (Sudbury, Mass.)

SN - 1528-9117

IS - 6

ER -